Brain exercise vs brain training.

The brain-training category accumulated a specific kind of regulatory exposure. In January 2016 the FTC announced a $2 million settlement with Lumos Labs, the maker of Lumosity, over what the agency called "deceptive advertising" (FTC press release). The complaint identified specific marketing claims as problematic — that Lumosity could help users perform better at school and work, reduce or delay the effects of age-related cognitive decline, and offer protection against Alzheimer's disease. The settlement required Lumosity to notify subscribers and offer cancellations, and the FTC's public statement noted that the brain-training industry had "preyed on consumers' fears about age-related cognitive decline".

The scientific record runs in parallel. In 2014 a group of cognitive scientists and neuroscientists, working through Stanford's Center on Longevity and the Max Planck Institute for Human Development, published a consensus statement responding to brain-training industry marketing (Stanford consensus; Science coverage). The statement, signed by more than seventy scientists, did not say brain-training games were worthless — it said there was "little evidence that playing brain games improves underlying broad cognitive abilities, or that it enables one to better navigate a complex realm of everyday life." The framing matters: the consensus targeted the marketing promise of transfer to real-world ability, not the activities themselves.

Daniel Simons and colleagues published a comprehensive review in 2016 — the same year as the FTC action — in Psychological Science in the Public Interesttitled "Do 'Brain-Training' Programs Work?". The review surveyed the published evidence base for commercial brain-training products and concluded that while practice produces improvement on the trained tasks themselves, evidence for far transfer — generalisation to untrained cognitive abilities or real-world performance — was weak (PMC summary; full text).

On the brain-exercise side, the framing is closer to physical exercise messaging: the value is in the regular doing, not in a claim about clinical outcome. The intellectual lineage is Anders Ericsson's deliberate-practice tradition — the 1993 paper that introduced the concept formally (Ericsson, Krampe & Tesch-Römer, 1993) — and its argument that the gains from practice are specific to the structure of what is being practised. That keeps the promise inside what a daily-practice app can actually deliver.

None of this is a claim that brain training as a research field is invalid. Cognitive science has many useful results, and some commercial products in the broader category have actual evidence behind specific claims. The clearest example is BrainHQ, whose "speed of processing" training traces to the one ACTIVE Trial arm that showed real-world transfer — the NIH-funded ACTIVE Trial being a twenty-year longitudinal study of cognitive interventions in older adults. Senwitt's comparison page for BrainHQ covers this honestly.

The FTC action against Lumosity does not say all brain-training products are deceptive. It is a specific action against a specific set of marketing claims by a specific company. The Stanford consensus does not say cognitive games are harmful. It says the broad-transfer marketing claims of the industry are not supported by the evidence base as it stood in 2014. The Simons review does not say practice has no value — it carefully distinguishes near transfer (improvement on the trained task) from far transfer (generalisation), and finds the evidence stronger for the former.

The issue throughout is specifically with broad marketing claims that outran the evidence. Senwitt's framing sidesteps that gap by not making those claims in the first place.

For Senwitt the practical consequence is everywhere on the site: the hero, the product explanation, the claim-boundary block, the comparison pages, and the press boilerplate all use brain-exercise language and avoid brain-training language. The category itself is the moat. We do not promise transfer. We promise practice.

This also shapes how comparison pages are written. When a competitor sits in the brain-training category with its broader marketing claims, the comparison page draws the distinction honestly. When a competitor sits inside the narrower band of evidence — BrainHQ, for example — the comparison page acknowledges the evidence and explains that Senwitt is built around a different category-level promise, not a stronger one.

For users, the practical implication is straightforward: if you want a product that promises to make you smarter, raise your IQ, or prevent cognitive decline, Senwitt is not that product. If you want a daily seven-minute place to practise six thinking skills that AI tools quietly take over, that is the product Senwitt is built to be.